Mr. Chair, I'd like to remind the member that the U.S. situation is different than Canada's. Going back to his earlier question and comment, the U.S. has continuously supported innovation in the life sciences sector and, therefore, has a different reason to discuss and potentially disclose relative elements of the contract.
We would encourage Canada to consider adopting more favourable policies and positions that would foster innovation in the life sciences sector and the biopharmaceutical industry going forward to increase resilience.